NasdaqGS - Delayed Quote USD

Editas Medicine, Inc. (EDIT)

5.32 +0.10 (+1.92%)
At close: April 26 at 4:00 PM EDT
5.39 +0.07 (+1.32%)
After hours: April 26 at 6:22 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Gilmore O'Neill M.D. President, CEO & Director 1.04M -- 1964
Mr. Erick J. Lucera C.F.A., CPA CFO & Executive VP 911.46k -- 1968
Dr. Linda C. Burkly Ph.D. Executive VP & Chief Scientific Officer 522.44k -- 1957
Dr. Baisong Mei M.D., Ph.D. Executive VP & Chief Medical Officer 654.9k -- 1964
Dr. Feng Zhang Ph.D. Co-Founder & Scientific Advisory Board Member -- -- --
Dr. George McDonald Church Ph.D. Co-Founder & Scientific Advisory Board Member -- -- 1954
Cristi Barnett Corporate Communications & Investor Relations -- -- --
Ms. Charlene Stern J.D., Ph.D. Executive VP & General Counsel -- -- --
Ms. Linea Aspesi Executive VP & Chief People Officer -- -- 1970
Ms. Caren Deardorf Executive VP and Chief Commercial & Strategy Officer -- -- 1966

Editas Medicine, Inc.

11 Hurley Street
Cambridge, MA 02141
United States
617 401 9000 https://www.editasmedicine.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
265

Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Corporate Governance

Editas Medicine, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 03, 2024 - May 07, 2024
Editas Medicine, Inc. Earnings Call

Related Tickers

NTLA Intellia Therapeutics, Inc.
20.76
+3.70%
 
BEAM Beam Therapeutics Inc.
21.38
-1.02%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
CRBU Caribou Biosciences, Inc.
3.7100
-1.33%
 
VERV Verve Therapeutics, Inc.
6.16
-0.96%
 
BLUE bluebird bio, Inc.
0.9228
+1.13%
 
PRME Prime Medicine, Inc.
4.4250
+2.91%
 
FATE Fate Therapeutics, Inc.
3.8000
-1.81%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%